Iovance Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Okay. Hello, everyone. Thanks again for joining us on day two of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach, I'm one of the biotech analysts here at Oppenheimer.
This afternoon, I'm pleased to be hosting a fireside chat with Iovance, which is developing a pipeline of tumor infiltrating lymphocyte, or TIL, cellular therapies for cancer. We believe Iovance's a lead product candidate lifileucel could receive accelerated approval later this year.
And joining us for today's discussion is the company's CFO, Jean-Marc Bellemin. We'll be sure to leave -- try to leave a few minutes at the end for Q&A. So feel free to make use of the question -- ask-a-question button on your browser if you want to submit anything to me to relay to Jean-Marc. But with that said, let's go ahead and dive right into the discussion.
So Jean-Marc, first of all, thanks for joining us today. And I hope you don't mind if I ask you some questions that are a little more focused on regulatory issues than on financial issues
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
